Search: Novo Nordisk's

Health

2 sources

Who is covering this

ReutersCenter

Yahoo NewsCenter

Truth score 531 2 days ago

Centre 100%100%

ReutersCenter2 days ago

Novo Nordisk's Wegovy pill beats forecasts as it battles Lilly

Novo Nordisk's Wegovy pill beats forecasts as it battles Lilly Reuters

Lean: Center Fact-focusedFactuality: Very highCountry: United KingdomFunding: CorporateOwner: Thomson Reuters

Yahoo News Novo Nordisk's CEO says only the Covid vaccine beat this launch | Sozzi Unleashed 2 days ago

Mike Doustdar took over at Novo Nordisk in August 2025, and he tells Brian Sozzi the obesity pill has had the biggest launch of any product he can think of apart from the Covid vaccine. It is on sale in eight...
Lean: Center VideoFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Apollo Global Management

Full coverage

Coverage breakdown

Funding

Corporate100%

Countries

United Kingdom50%

United States50%

Media ownership

Thomson Reuters50%

Apollo Global Management50%

Avg reliability81

Low-credibility share0%

Fact / opinion2/0

State media0%

More analysis

Truth score: 53 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 2 Reliability: 81 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Coverage Heat Map

Like

Business

3 sources

Who is covering this

CNBCCenter

Google NewsCenter

LivemintCenter

Truth score 58 1 day ago

Centre 100%100%

CNBCCenter1 day ago

CVS Health plans to split itself up. Here's why a breakup could make sense now

Analysts say that after a roughly two-year turnaround the company's retail pharmacy business and other units may be strong enough to stand on their own. Covered by 3 outlets: 3 are centre.

Lean: Center Fact-focusedFactuality: HighCountry: United StatesFunding: Corporate

Google News Inside CVS’s Decision to Break Up a Healthcare Juggernaut - WSJ 1 day ago

Inside CVS’s Decision to Break Up a Healthcare Juggernaut WSJ CVS to split off drugstore business in major breakup of healthcare giant; shares fall 10% CNBC CVS to break up $117 billion business, separating...
Lean: Center Fact-focusedFactuality: HighCountry: United StatesFunding: Corporate
Livemint CVS Health Split: Healthcare giant to separate 9,000 stores in one of the industry's biggest-ever breakups 2 days ago

CVS Health plans to separate its roughly 9,000 retail pharmacies into a publicly traded company, CVS Pharmacy, in the first half of 2028. CVS Health will retain Aetna and Caremark. The move follows a strategic review...
Lean: Center Fact-focusedCountry: IndiaFunding: CorporateOwner: Independent

+ 1 · Full coverage

Coverage breakdown

Funding

Corporate100%

Countries

United States67%

India33%

Media ownership

Independent33%

CNBC33%

Google News33%

Avg reliability78

Low-credibility share0%

Fact / opinion4/0

State media0%

More analysis

Truth score: 58 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 3 Reliability: 78 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 8 Amplification: 0

How we score

Analyze: Compare coverage

Like

World

1 source

Who is covering this

The Epoch TimesRight

Truth score 17Factuality: Low 2 days ago

Right 100%100%

The Epoch TimesRight2 days ago

First Weight-Loss Tablet Approved for Use in Australia

Low reliability sourceElevated risk

A sign bearing the logo of Novo Nordisk next to the company's factory in Hillerod, Denmark, on Nov. 12, 2025. (Sergei Gapon/AFP via Getty Images)

Lean: Right Fact-focusedFactuality: LowCountry: United StatesFunding: PrivateOwner: Epoch Media Group

Full coverage

Coverage breakdown

Funding

Private100%

Countries

United States100%

Media ownership

Epoch Media Group100%

Avg reliability35

Low-credibility share100%

Fact / opinion1/0

State media0%

More analysis

Truth score: 17 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 35 Bias severity: 0 Risk: 100Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Coverage Heat Map

Like

1 source

Who is covering this

CNBCCenter

Truth score 43 2 days ago

Centre 100%100%

CNBCCenter2 days ago

Novo raises full-year outlook as Wegovy pill sales impress

Novo posted quarterly earnings ahead of expectations early Wednesday as sales of its Wegovy pill blew past estimates

Lean: Center Fact-focusedFactuality: HighCountry: United StatesFunding: Corporate

Full coverage

Coverage breakdown

Funding

Corporate100%

Countries

United States100%

Media ownership

CNBC100%

Avg reliability80

Low-credibility share0%

Fact / opinion1/0

State media0%

More analysis

Truth score: 43 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 80 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Story Timeline

Like

Entertainment

1 source

Who is covering this

DeadlineCenter

Truth score 41 1 day ago

Centre 100%100%

DeadlineCenter1 day ago

Narrative Global Sales Takes Three Genre Films To AFM Including Jenna Kanell Sci-Fi ‘De Novo’ With Lilly Wachowski Aboard

EXCLUSIVE: Lilly Wachowski’s Anarchists United with Sarah Marie Flores and Lawrence Mattis have joined the upcoming sci-fi film De Novo as executive producers. Written and directed by Terrifier actress Jenna Kanell, and currently in...

Lean: Center Fact-focusedFactuality: HighCountry: United StatesFunding: CorporateOwner: Penske Media Corporation

Full coverage

Coverage breakdown

Funding

Corporate100%

Countries

United States100%

Media ownership

Penske Media Corporation100%

Avg reliability75

Low-credibility share0%

Fact / opinion1/0

State media0%

More analysis

Truth score: 41 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 75 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Coverage Heat Map

Like

Health

1 source

Who is covering this

MedscapeCenter

Truth score 38 2 days ago

Centre 100%100%

MedscapeCenter2 days ago

DCBs Hold Their Own Against Stents in De Novo Lesions

In noncomplex coronary artery disease, a drug coated-balloon is noninferior to a drug-eluting stent at 12 months.

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent

Full coverage

Coverage breakdown

Funding

Corporate100%

Countries

United States100%

Media ownership

Independent100%

Avg reliability65

Low-credibility share0%

Fact / opinion1/0

State media0%

More analysis

Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Coverage Heat Map

Like

Health

1 source

Who is covering this

MedpagetodayCenter

Truth score 38 3 days ago

Centre 100%100%

MedpagetodayCenter3 days ago

Study Strengthens Case for Stent-Free PCI in De Novo Coronary Lesions

(MedPage Today) -- For de novo coronary lesions, drug-coated balloons (DCBs) were just as effective as standard drug-eluting stents, the TRANSFORM II trial showed. Among patients with native coronary lesions undergoing percutaneous...

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent

Full coverage

Coverage breakdown

Funding

Corporate100%

Countries

United States100%

Media ownership

Independent100%

Avg reliability65

Low-credibility share0%

Fact / opinion1/0

State media0%

More analysis

Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Misinfo Radar

Like

Filter the stories

Sources Ratings and details

Results for “Novo Nordisk's”

Novo Nordisk's Wegovy pill beats forecasts as it battles Lilly

CVS Health plans to split itself up. Here's why a breakup could make sense now

First Weight-Loss Tablet Approved for Use in Australia

Novo raises full-year outlook as Wegovy pill sales impress

Narrative Global Sales Takes Three Genre Films To AFM Including Jenna Kanell Sci-Fi ‘De Novo’ With Lilly Wachowski Aboard

DCBs Hold Their Own Against Stents in De Novo Lesions

Study Strengthens Case for Stent-Free PCI in De Novo Coronary Lesions